茵栀黄口服液治疗新生儿高胆红素血症的效果-国际中医药研究-CSCIED科技核心评价数据库-手机版

茵栀黄口服液治疗新生儿高胆红素血症的效果

Effect of Yinzhihuang oral liquid on neonatal hyperbilirubinemia

ES评分 0 浏览量：1403 下载量：0

DOI	10.12208/j.ircm.20230013
刊名	国际中医药研究 International Research in Chinese Medicine
年，卷(期)	2023, 3(2)
作者	崔桂云*,
作者单位	临淄区皇城中心卫生院山东淄博 ;
摘要	探讨茵栀黄口服液应用在新生儿高胆红素血症的临床价值。方法对我院2020年3月-2021年5月收治的72例新生儿高胆红素血症作为此次研究病例，按照随机数字表法分组，研究组和参照组各36例，参照组用蓝光治疗，研究组在参照组基础上加用茵栀黄口服液，比较两组的临床效果与不良反应发生率，并评估两组治疗后第1/2/3/4/5/6天总胆红素含量、直接胆红素含量。结果研究组临床有效率（91.67%）高于参照组（69.44%），与参照比较，研究组每日粪便中总胆红素含量多，直接胆红素含量多，研究组不良反应发生率（5.56%）低于参照组（27.78%），研究组的PDI、MDI水平低于参照组，差异呈P<0.05。结论茵栀黄口服液治疗新生儿高胆红素血症的疗效确切，可改善患儿的总胆红素与直接胆红素含量水平，提高治疗效果，安全性高，值得推广应用。
Abstract	Objective To explore the clinical value of Yinzhihuang oral liquid in the treatment of neonatal hyperbilirubinemia. Methods 72 cases of neonatal hyperbilirubinemia admitted to our hospital from March 2020 to May 2021 were selected as the study cases. They were randomly divided into two groups according to the number table method. The study group and the reference group each had 36 cases, and the reference group were treated with blue light. The study group added Yinzhihuang oral liquid to the reference group, and compared the clinical effects and adverse reaction rates of the two groups. The total bilirubin content and direct bilirubin content of the two groups on the 1st/2nd/3rd/5th/6th day after treatment were evaluated. Results The clinical effective rate of the study group (91.67%) was higher than that of the reference group (69.44%). Compared with the reference group, the daily total bilirubin content in the feces of the study group was higher, and the direct bilirubin content was higher. The incidence of adverse reactions in the study group (5.56%) was lower than that of the reference group (27.78%). The levels of PDI and MDI in the study group were lower than that of the reference group, with a difference of P<0.05. Conclusion Yinzhihuang oral liquid is effective in the treatment of neonatal hyperbilirubinemia, can improve the levels of total bilirubin and direct bilirubin in children, improve the treatment effect, and has high safety. It is worth promoting and applying.
关键词	茵栀黄口服液；新生儿；高胆红素血症；总胆红素；直接胆红素
KeyWord	Yinzhihuang oral liquid; Newborn; Hyperbilirubinemia; Total bilirubin; Direct bilirubin
基金项目
页码	32-35

参考文献
相关文献

[1] 张强,王秋霞,常明.茵栀黄口服液联合布拉氏酵母菌散辅助治疗新生儿高胆红素血症的疗效分析
[J].黑龙江医学,2022,46(24):2983-2986.

[2] 蒋国峰,华鹏,洪林星.茵栀黄口服液联合蓝光照射疗法、中医穴位推拿治疗新生儿高胆红素血症的临床疗效
[J].临床合理用药杂志,2022,15(33):135-138.

[3] 吴新婷,卞伟妮,郑玲芳,孟远翠,常盼,贾南.口服益生菌联合茵栀黄口服液治疗新生儿高胆红素血症的效果及免疫机制分析
[J].中国医药,2022,17(07):1029-1033.

[4] 朱惠洁,卢君,曹巧玲,任颖俊.小儿推拿联合强光疗法与茵栀黄口服液联合强光疗法治疗新生儿高胆红素血症的疗效比较
[J].中国妇幼保健,2021,36(01):208-210.

[5] 赵乔.微生态制剂联合茵栀黄口服液用于治疗新生儿高胆红素血症的临床研究
[J].医学食疗与健康, 2020, 18(23): 217-218.

[6] 胡宁,王卫平.茵栀黄口服液联合蓝光照射治疗新生儿高胆红素血症的疗效观察
[J].四川解剖学杂志, 2020, 28(03): 111-112.

[7] Wu RH, Feng S, Han M, Caldwell P, Liu SG, Zhang J, Liu JP. Yinzhihuang oral liquid combined with phototherapy for neonatal jaundice: a systematic review and meta-analysis of randomized clinical trials. BMC Complement Altern Med. 2018 Jul 28;18(1):228.

[8] 杨庆.蓝光照射联合茵栀黄口服液治疗重度新生儿高胆红素血症的临床研究
[J].系统医学,2020,5(17):105-107.

[9] 曹红利,王婷.茵栀黄口服液联合蓝光治疗新生儿高胆红素血症的临床效果
[J].临床医学研究与实践, 2020, 5(07): 135-137.

[10] Han J, Li C, Dai Z, Duan J, Cai W, Wang Y, Zhang Y. Yinzhihuang Oral Liquid Ameliorates Hyperbilirubinemia Induced by δ-Aminolevulinic Acid and Novobiocin in Neonatal Rats. Chem Biodivers. 2021 Aug; 18(8): e2100222.

[11] 高大明,马家明,刘永红,翟爱国,韦辉.茵栀黄口服液、双歧杆菌联合蓝光照射治疗新生儿高胆红素血症的临床效果
[J].临床医学研究与实践,2019,4(08):92-93+102.

[12] 丁丽红,刘帅,熊其江.短时多次及持续蓝光照射联合茵栀黄口服液对新生儿高胆红素血症患儿神经因子的影响
[J].临床医药文献电子杂志,2019,6(13):36+38.

[13] 陈凯权,马进,方开峰.茵栀黄口服液联合布拉酵母菌治疗新生儿高胆红素血症的疗效
[J].世界中医药, 2020, 15(16): 2418-2421+2425.

引用本文

崔桂云*. 茵栀黄口服液治疗新生儿高胆红素血症的效果 [J]. 国际中医药研究. 2023; 3; (2). 32 - 35.

文献评论

相关学者

相关机构